Shimadzu Corporation 7701
TSE · Japan · Health Technology
¥3,996.00-60.00 (-1.48%)
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
The global mass spectrometry market is projected to grow from USD 7.07 billion in 2026 to USD 10.78 billion by 2031, at an 8.8% CAGR. Growth is driven by precision medicine, biologics, multi-omics research, regulatory bioanalysis, and food and environmental testing. Instruments and LC-MS will lead the market, supported by high-resolution platforms, AI-enabled analytics, automation, and cloud-connected workflows. Pharmaceutical companies remain the largest end users, while Asia Pacific is expecte
The global life science instrumentation market is forecasted to grow from USD 63.4 billion in 2025 to USD 92.5 billion by 2031, at a CAGR of 6.5%. Key drivers include increased R&D funding, rising proteomics research, and growing disease prevalence. In 2025, the spectroscopy segment dominated the market owing to its integration in pharmaceutical and biotechnology research. The research applications sector is set to achieve the highest growth, with significant strides in genomics and drug discove
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.